Tardive Dyskinesia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug (Deutetrabenazine, Valbenazine, and Others); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024 – 2032
- Published Date:Mar-2024
- Pages: 117
- Format: PDF
- Report ID: PM4423
- Base Year: 2023
- Historical Data: 2019-2022
Report Outlook
The global tardive dyskinesia therapeutics market was valued at USD 3.83 billion in 2023 and is expected to grow at a CAGR of 4.3% during the forecast period.
The continuous increase in the number of schizophrenia patients worldwide and growing incidences of neurological disorders because of long-term use of antipsychotic drugs by these patients that increases the risk of tardive dyskinesia, driving its market’s growth. The growing investments on research & development activities that lead to advancements and improvements in tardive dyskinesia therapeutics, are also driving the global market growth.
- For instance, according to a report published by the World Health Organization, schizophrenia affects approx. 24 million people worldwide that means every 1 in 300 people are suffering with this. People with schizophrenia are 2 to 3 times more likely to die early than normal population that is mainly due to their physical illnesses like cardiovascular and infectious diseases.
Moreover, the rapid surge in the awareness and knowledge among leading healthcare organizations and professionals about the symptoms associated with tardive dyskinesia which results in early diagnosis and treatment of the diseases, is positively influencing the market’s growth. In addition, rising number of healthcare institutions and government agencies implementing on favorable initiatives, grants, and support for the research activities that led to the advancements in market and opening new growth opportunities. For example, according to a report by the Economic Times in April 2023, Department of Science & Technology, India, provides funding for R&D projects and supporting the establishment of research institutions.
To Understand More About this Research:Request a Free Sample Report
However, lack of awareness among patients about this disorder and their symptoms especially in low-and-middle income countries and limited R&D investments by pharmaceutical companies because of the comparatively small patient population, are the factors that could restrain global market growth in the near future.
Industry Dynamics
Growth Drivers
- Increasing prevalence of tardive dyskinesia and focus of companies on gaining product approvals are propelling market growth
There is an increasing prevalence of tardive dyskinesia worldwide that increased the demand for effective treatment and therapeutics solutions. As it is a critical type of movement disorder which occurs as a side effect of long-term usage of various types of psychiatric medications like antipsychotics. Additionally, there are numerous companies in the market focusing on gaining product approvals from various regulatory authorities including US Food and Drug Administration, with aim to expand their market presence and product offerings, which will also propel market’ growth.
- For instance, in December 2021, Intra-Cellular Therapies Inc, announced about the approval from US Food and Drug Administration for CAPLYTA for the treatment of depressive episodes associated with bipolar I or II disorder in adults.
Report Segmentation
The market is primarily segmented based on drug, product type, distribution channel, and region.
|
By Drug |
By Product Type |
By Distribution Channel |
By Region |
|
|
|
|
To Understand the Scope of this Report:Speak to Analyst
By Drug Analysis
- Valbenazine segment accounted for the largest market share in 2023
The valbenazine segment accounted for the largest share. Segment’s dominance is attributed to widespread use and availability of these types of drugs in developed countries and continuous surge in the number of companies introducing their awareness programs to make people aware about the disease, their symptoms, and available treatment options.
By Product Type Analysis
- Solid dosage form segment held the majority market share in 2023
The solid dosage form segment held the majority share. This dominance is attributed to their widespread adoption by various healthcare professionals and patients due to its ability to provide higher stability of the active pharmaceutical ingredient that ensures the effectiveness of medication, which is very crucial for managing diseases like tardive dyskinesia.
The capsules segment is also projected to exhibit highest growth rate, due to rising adoption of capsules as they are especially formulated and designed with medications that have significantly demonstrated efficacy in managing symptoms of these health diseases.
By Distribution Channel Analysis
- Online pharmacies segment is expected to witness highest growth
The online pharmacies segment will grow at highest pace. This growth is attributable to rapid emergence of various online pharmacies as they provide numerous beneficial characteristics including easy access to healthcare data and allow patients to consult with healthcare professionals, results in time saving for patients which is especially crucial in urban regions. Also, the continuous increase in the number of digital buyers worldwide and focus on companies towards telemedicine integration into online pharmacies to allow patients to consult with healthcare professionals, will also boost segment’s growth.
- For instance, according to a study conducted by the PubMed Central, 82.65% of the respondents said that they were aware about the availability of medications through online, and approx. 9.47% stated that they were very likely to purchase medications online.
The hospital pharmacies segment led the market. This dominance is attributed to constant expansion of healthcare infrastructure in growing economies and wider availability of therapeutics and treatments of such diseases in hospitals compared to other channels.
Regional Insights
- North America region dominated the global market in 2023
The North America region dominated the global market. Region’s dominance is accelerated by rapid increase in awareness among population about the disease and its potential symptoms that led to increased number of patients undergoing treatment and opting for therapeutics. Also, the region’s growing elderly population who are more likely and prone to these types of diseases will boost demand for these therapeutics.
- For instance, according to a report published by United States Census Bureau, the U.S. population of people aged 65 years and above has grown by about five times faster than the total population over the last 100 years. Currently, the elderly population of U.S. reached 55.8 million people that makes up 16.8% of total population in 2020.
Furthermore, the rapid advances in research & development for the creation of new therapeutic approaches as well as improved treatment options and robust presence of regulatory authorities that promotes the development of new drugs and treatment therapies like US FDA, are also likely to create substantial growth.
Asia Pacific projected to grow fastest, on account of growing research & development activities by regional companies to develop advanced and more effective treatment solutions for tardive dyskinesia. In addition, the continuous surge in patient pool of schizophrenia, bipolar, and many other neuroleptic disorders, is also anticipated to boost region’s growth. For instance, according to the World Health Organization, more than 60 to 70 million people in India suffer from severe and common mental disorders including anxiety, bipolar, and schizophrenia.
Key Market Players & Competitive Insights
The tardive dyskinesia therapeutics market is highly fragmented in nature with the robust presence of global market players. The key players are constantly bringing new innovations and performing various clinical trails for the development and creation of novel drugs. Also, key players are competing on various factors such as obtaining regulatory approvals from health authorities, improving efficacy of therapies, and developing patient access programs, which led to higher competitiveness in the market. For instance, in June 2022, Mitsubishi Tanabe Pharma Corporation, announced the launch of its DYSVAL capsule 40mg for the treatment of the tardive dyskinesia. It is the first drug to be approved in Japan for the treatment of tardive dyskinesia.
Some of the major players operating in the global market include:
- Allergan
- Contera Pharma
- Johnson & Johnson Services Inc.
- Lannett Co. Inc.
- Luye Pharma Group
- Mitsubishi Tanabe Pharma Corporation
- Neurocrine Biosciences Inc.
- Prestwick Pharmaceuticals Inc.
- Reddy Laboratories Ltd.
- SOM Biotech
- SteriMax Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Valeant Pharmaceuticals
Recent Developments
- In February 2023, Teva, announced that they have gained an FDA approval for drug Austedo. The new formulation is more easier to take in the morning.
- In August 2023, Neurocrine Biosciences, announced that the US FDA approved INGREZZA capsules for the treatment of adults with chorea. The newly developed capsule is the only selective vesicular monoamine transporter 2 inhibitor.
Tardive Dyskinesia Therapeutics Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 3.98 billion |
|
Revenue forecast in 2032 |
USD 5.57 billion |
|
CAGR |
4.3% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Segments covered |
By Drug, By Product Type, By Distribution Channel, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
FAQ's
Tardive Dyskinesia Therapeutics Market report covering key segments are drug, product type, distribution channel, and region.
Tardive Dyskinesia Therapeutics Market Size Worth $ 5.57 Billion By 2032.
The global tardive dyskinesia therapeutics market is expected to grow at a CAGR of 4.3% during the forecast period.
North America is leading the global market.
The key driving factors in Tardive Dyskinesia Therapeutics Market Research and Development Initiatives.
